Sort by
Preoperative Central Sensitization Worsens Pain and Dissatisfaction Following Unicompartmental Knee Arthroplasty
Man Soo Kim,
Keun Young Choi,
Yong In
Posted: 17 April 2025
Cultivating Self-Compassion to Improve Social Workers’ Professional Quality of Life in Primary Healthcare
Polyxeni Mangoulia,
Nektarios Tsokas,
Evmorfia Koukia,
Foteini Malli,
Evdokia Misouridou,
Chrysoula Dafogianni,
Maria Kyranou,
Evangelos C. Fradelos
Posted: 09 April 2025
Patient Satisfaction in Primary and Specialized Ambulatory Healthcare: A Web-Based Cross-Sectional Study in the Polish Population
Agnieszka Pochrzęst-Motyczyńska,
Janusz Ostrowski,
Dorota Sys,
Jarosław Pinkas,
Religioni Urszula
Posted: 08 April 2025
High School Student’s Perceptions of Factors Related to Zoonotic Diseases
Ronaldo Alves Pereira-Junior,
Isabella Marques Nascimento,
Maria Eduarda Barbiéri-Machado,
Lorena Lopes Ferreira
Posted: 03 April 2025
Parent Perceptions of an Anxiety Prevention Manual for Young Children
Olutosin Sanyaolu,
Ava Robertson,
Tabitha Naa Akuyea Addy,
Laura Anne Nabors
Posted: 01 April 2025
Prediction of Microvascular Adaptation to Hypoxia Based on Myogenic Microcirculation Oscillations
Andrzej Marcinek,
Joanna Katarzynska,
Artur Stanek,
Jerzy Gebicki
Posted: 28 March 2025
Clinical MRSA Profiles Reveal Age- and Gender-Specific Transmission Dynamics in a Tertiary Care Hospital: High Burden in ICU Elderly and Emerging Community Patterns in Youth
Kamaleldin B Said,
Khalid F Alshammari,
Ruba M. Elsaid Ahmed,
Fawwaz Alshammari,
Ahmed H. Aljadani,
Ehab Rakha,
Salem A Almijrad,
Anwar E. Almallahi,
Bader I Alkharisi,
Naif M Altamimi
Posted: 26 March 2025
Interim Report from the Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients with Chronic Obstructive Pulmonary Disease (PROMISE) Evaluation
Eric Harker
Posted: 24 March 2025
Modelling Prevention and Control of the Emerging Infectious Disease of Village Health Volunteer : A Path Analysis
Wuttiphong Phakdeekul,
Nitikorn Phoosuwan,
Kittisak Nuanchum,
Pongsakorn Boonmatoon,
Warinmad Kedthongma
Posted: 24 March 2025
Clinical Pathologic Screening for Helicobacter pylori in Outpatients Reveal Age-Specific Peaking with Concomitant Chronic-Gastric Inflammation, Robust Immunity, and Tissue Alterations Implying Potential Predisposition to Malignancy
Kamaleldin B. Said,
Khalid F. Alshammari,
Safia Moussa,
Ruba M. Elsaid Ahmed,
Ahmed H. Aljadani,
Najd B. Albalawi,
Layan Al-Hujaili,
Ruaa Alharbi,
Arwa A. Alotaibi,
Fahad M. Alshammary
Posted: 18 March 2025
Pseudobulbar Affect in Dementia: Neuropsychiatric Associations and Subtype Differences
Ozlem Totuk,
Merve Türkkol,
Güldeniz Cetin Erci,
Sevki Sahin,
Serkan Demir
Posted: 17 March 2025
Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice
Takafumi Tanei,
Shun Yamamoto,
Satoshi Maesawa,
Yusuke Nishimura,
Tomotaka Ishizaki,
Yoshitaka Nagashima,
Yoshiki Ito,
Miki Hashida,
Takahiro Suzuki,
Hajime Hamasaki
Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There were four reasons for prescribing lasmiditan: add-on to triptan, ineffectiveness of triptan, side effects of triptan, and triptan contraindicated. Lasmiditan was started at a dose of 50 mg. Efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraine who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in male, severe migraine classification, and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.
Background/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There were four reasons for prescribing lasmiditan: add-on to triptan, ineffectiveness of triptan, side effects of triptan, and triptan contraindicated. Lasmiditan was started at a dose of 50 mg. Efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraine who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54/108). The following factors were found to be associated with lasmiditan efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in male, severe migraine classification, and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.
Posted: 13 March 2025
Blood Disease Risk Assessment – a ComparativeAnalysis of Machine Learning Models and XAIbased Model Interpretability
Chameera De Silva,
Thilina Halloluwa
Healthcare sector has always been one of themost important industries for humankind. As ArtificialIntelligence is automating several industries, use of AI andmachine learning based algorithms in healthcare is anincredible idea to improvise the way we look towards andperform healthcare. One of the best ways to bring an AI/MLbased change in healthcare is through first-hand diagnosis ofdiseases. There are numerous blood related diseases, presence,or risk of which can be assessed through analysing the basicblood report of a patient. Developing a machine learningmodel to perform this analysis and flash the comments ‘risk’or ‘no risk’ on screen in seconds would be a big advancementin the diagnosis sector, saving a lot of time and man force. Thisresearch paper develops machine learning models to performthis first-hand blood related disease risk assessment and alsoexplores the processing of these black-box models throughexplainable AI (XAI) to ensure the trustworthiness of thesemodels for using them at scale. The machine learning modelstrained and tested for the blood disease risk assessment areLogistic Regression, Decision Tree, Random Forest andXGBoost and the best test accuracy obtained from thesemachine learning models is 100%. The feature contributingthe most to the prediction as recorded by XAI are MCV,MCH, HBG and HBA.
Healthcare sector has always been one of themost important industries for humankind. As ArtificialIntelligence is automating several industries, use of AI andmachine learning based algorithms in healthcare is anincredible idea to improvise the way we look towards andperform healthcare. One of the best ways to bring an AI/MLbased change in healthcare is through first-hand diagnosis ofdiseases. There are numerous blood related diseases, presence,or risk of which can be assessed through analysing the basicblood report of a patient. Developing a machine learningmodel to perform this analysis and flash the comments ‘risk’or ‘no risk’ on screen in seconds would be a big advancementin the diagnosis sector, saving a lot of time and man force. Thisresearch paper develops machine learning models to performthis first-hand blood related disease risk assessment and alsoexplores the processing of these black-box models throughexplainable AI (XAI) to ensure the trustworthiness of thesemodels for using them at scale. The machine learning modelstrained and tested for the blood disease risk assessment areLogistic Regression, Decision Tree, Random Forest andXGBoost and the best test accuracy obtained from thesemachine learning models is 100%. The feature contributingthe most to the prediction as recorded by XAI are MCV,MCH, HBG and HBA.
Posted: 11 March 2025
Quantitative Sensory Testing in Fibromyalgia Syndrome: A Scoping Review
Adriana Munhoz Carneiro,
Camila Dalle,
Marina de Góes Salvetti,
Valquíria Aparecida da Silva
Posted: 11 March 2025
Digital Health Interventions and Access to Primary Health Care in Australia: Successes and Challenges
Siyu Zhai,
Resham Bahadur Khatri,
Yibeltal Assefa Alemu
Posted: 11 March 2025
Towards Evaluating the Diagnostic Ability of LLMs
Peter Sarvari,
Zaid Al-fagih
Posted: 07 March 2025
Unlocking Relief: A Pilot Investigation of the Impact of a Probiotic, Enzyme, and Melissa Officinalis Combination on Bloating and Digestive Wellness in IBS Patients
Daniela Pinto,
Giorgia Mondadori,
Fabio Rinaldi,
Luca Elli,
Vincenza Lombardo,
Alice Scricciolo,
Andrea Costantino,
Anna Fichera,
Beatrice Rota,
Rossella Marrazzo
Background: Functional gastrointestinal disorders, including irritable bowel syndrome (IBS) and functional abdominal bloating, are prevalent in gastroenterology. The unclear pathogenesis complicates the development of effective therapies, which may be pharmacological or non-pharmacological in nature. Objective: This pilot study aimed to evaluate the efficacy of a food supplement containing probiotics, digestive enzymes, and Melissa officinalis extract in patients suffering from IBS and functional abdominal bloating. Methods: We conducted a randomized, double-blind, placebo-controlled, monocentric trial involving adult patients diagnosed with IBS and functional abdominal bloating. Participants were randomly assigned to receive either the active product or a placebo for 20 days. The primary outcome measure was the change in the global Visual Analogue Scale (VAS) for satisfaction. Secondary measures included symptom scales related to bloating and abdominal pain. Results: A total of 31 participants were enrolled, with 29 completing the study. Patients receiving the active supplement reported a positive effect in the global VAS for satisfaction and demonstrated improvement in most secondary symptom scales compared to the placebo group. However, no statistically significant differences were found between the active and placebo groups, the treatment resulted in a higher tendency to improvement in patient-reported outcomes compared to the placebo group. Conclusion: This pilot study provides valuable insights into non-pharmacological therapies for IBS and functional abdominal bloating. Although the results were promising, larger studies with longer treatment durations and based on more complex approach also including diet intervention and psychological support are needed to fully evaluate the long-term effects of probiotics and the active ingredients in the supplement.
Background: Functional gastrointestinal disorders, including irritable bowel syndrome (IBS) and functional abdominal bloating, are prevalent in gastroenterology. The unclear pathogenesis complicates the development of effective therapies, which may be pharmacological or non-pharmacological in nature. Objective: This pilot study aimed to evaluate the efficacy of a food supplement containing probiotics, digestive enzymes, and Melissa officinalis extract in patients suffering from IBS and functional abdominal bloating. Methods: We conducted a randomized, double-blind, placebo-controlled, monocentric trial involving adult patients diagnosed with IBS and functional abdominal bloating. Participants were randomly assigned to receive either the active product or a placebo for 20 days. The primary outcome measure was the change in the global Visual Analogue Scale (VAS) for satisfaction. Secondary measures included symptom scales related to bloating and abdominal pain. Results: A total of 31 participants were enrolled, with 29 completing the study. Patients receiving the active supplement reported a positive effect in the global VAS for satisfaction and demonstrated improvement in most secondary symptom scales compared to the placebo group. However, no statistically significant differences were found between the active and placebo groups, the treatment resulted in a higher tendency to improvement in patient-reported outcomes compared to the placebo group. Conclusion: This pilot study provides valuable insights into non-pharmacological therapies for IBS and functional abdominal bloating. Although the results were promising, larger studies with longer treatment durations and based on more complex approach also including diet intervention and psychological support are needed to fully evaluate the long-term effects of probiotics and the active ingredients in the supplement.
Posted: 07 March 2025
From Awareness to Advocacy: The Impact of Social Media on Healthcare Professionals
Asad Ali
Posted: 06 March 2025
Global Status of Adult Immunization Post COVID-19 Pandemic
Alba Vilajeliu,
Victor Vega,
Randie Gibson,
Francisco Nogareda,
Xiaojun Wang,
Donald Brooks,
Charles Shey Wiysonge,
Osman Niyazi Cakmak,
Osama Mere,
Melanie Marti
Background: Historically, immunization programmes have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. This manuscript provides a global overview of adult immunization post COVID-19 pandemic. Methods: We summarized WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations by adult group and analyzed the data reported in 2024 (2023) by WHO Member States (MS) via the WHO/UNICEF electronic Joint Reporting Form on Immunization (eJRF) on national immunization schedules, and from other sources by WHO region and income group. Results: WHO policy recommendations exist for most of the licensed vaccines targeting adults; however, the inclusion in national immunization schedules is higher in high-income (HICs) and middle-income (MICs) countries. For pregnant women, 90% of MS reported vaccination against COVID-19 (65% in low-income countries [LICs]), 63% against tetanus-containing vaccines (73% in LICs), 57% against influenza (4% in LICs), and 21% against pertussis-containing vaccines (all MICs and HICs). For health workers, 91% against COVID-19 (92% in LICs), 59% against influenza (4% in LICs), and 25% against hepatitis B (10% in LICs). For adults with chronic diseases, COVID-19 vaccination data were not available, 58% against influenza, and 23% against pneumococcal disease. For older adults, more than 90% of MS across all income groups reported COVID-19 vaccination, 59% against influenza (8% of LICs versus 89% of HICs), 17% against pneumococcal, and 7% against herpes zoster. Conclusion: The disparities in adult immunization policies across income groups highlight the need to improve access and strengthen vaccination efforts. A life course approach is essential to maximize the full potential of immunization across all ages.
Background: Historically, immunization programmes have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. This manuscript provides a global overview of adult immunization post COVID-19 pandemic. Methods: We summarized WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommendations by adult group and analyzed the data reported in 2024 (2023) by WHO Member States (MS) via the WHO/UNICEF electronic Joint Reporting Form on Immunization (eJRF) on national immunization schedules, and from other sources by WHO region and income group. Results: WHO policy recommendations exist for most of the licensed vaccines targeting adults; however, the inclusion in national immunization schedules is higher in high-income (HICs) and middle-income (MICs) countries. For pregnant women, 90% of MS reported vaccination against COVID-19 (65% in low-income countries [LICs]), 63% against tetanus-containing vaccines (73% in LICs), 57% against influenza (4% in LICs), and 21% against pertussis-containing vaccines (all MICs and HICs). For health workers, 91% against COVID-19 (92% in LICs), 59% against influenza (4% in LICs), and 25% against hepatitis B (10% in LICs). For adults with chronic diseases, COVID-19 vaccination data were not available, 58% against influenza, and 23% against pneumococcal disease. For older adults, more than 90% of MS across all income groups reported COVID-19 vaccination, 59% against influenza (8% of LICs versus 89% of HICs), 17% against pneumococcal, and 7% against herpes zoster. Conclusion: The disparities in adult immunization policies across income groups highlight the need to improve access and strengthen vaccination efforts. A life course approach is essential to maximize the full potential of immunization across all ages.
Posted: 05 March 2025
One-Year Changes in Depressive Symptoms and Cognitive Function Among Brazilian Older Adults Attending Primary Care
Fernanda Maria Silva Rivoli,
Antonio Pedro Gabriel Monteiro Galhardo,
Giancarlo Lucchetti,
Lízia Abreu Ésper,
Yan Lyncon Ribeiro,
Gerson Santos,
Helena José,
Luís Sousa,
Gail Low,
Luciano Magalhães Vitorino
Background: Aging is a global phenomenon closely associated to changes in cognitive function and mental health. These conditions substantially burden public health systems and adversely affect the quality of life of older adults. This study aimed to examine changes in depressive symptoms and cognitive function over a 12-month follow-up period in a cohort of Brazilian older adults attending primary care. Methods: This observational, longitudinal study included a randomized sample of individuals aged ≥60 years residing in São Paulo, Brazil, and registered at a Primary Healthcare Unit (PHU). Data collection involved administering a sociodemographic and health questionnaire along with two validated instruments: the Geriatric Depression Scale-15 (GDS-15) and the Mini-Mental State Examination (MMSE). Linear regression models were used for the analyses. Results: A total of 368 older adults were included, being 63% men and with a mean age of 74.65 years. After one year, depressive symptoms showed a notable increase, with the mean GDS-15 score rising from 5.97 to 7.48 (Cohen-d = 0.542). Likewise, there was a decrease in the mean MMSE score ranging from 19.11 to 18.88 (Cohen-d=0.216). Adjusted regression analyses revealed that depressive symptoms at baseline (B = 0.696; p = 0.048; R² = 0.19) and cognitive function at baseline (B = 0.444; p < 0.001; R² = 0.26) were predictive of their respective deteriorations over the follow-up period. Conclusion: Depressive symptoms and cognitive decline place a significant burden on public health systems in aging societies. These findings underscore the importance of continuous monitoring and early intervention strategies to mitigate their impact and enhance the quality of life for older adults.
Background: Aging is a global phenomenon closely associated to changes in cognitive function and mental health. These conditions substantially burden public health systems and adversely affect the quality of life of older adults. This study aimed to examine changes in depressive symptoms and cognitive function over a 12-month follow-up period in a cohort of Brazilian older adults attending primary care. Methods: This observational, longitudinal study included a randomized sample of individuals aged ≥60 years residing in São Paulo, Brazil, and registered at a Primary Healthcare Unit (PHU). Data collection involved administering a sociodemographic and health questionnaire along with two validated instruments: the Geriatric Depression Scale-15 (GDS-15) and the Mini-Mental State Examination (MMSE). Linear regression models were used for the analyses. Results: A total of 368 older adults were included, being 63% men and with a mean age of 74.65 years. After one year, depressive symptoms showed a notable increase, with the mean GDS-15 score rising from 5.97 to 7.48 (Cohen-d = 0.542). Likewise, there was a decrease in the mean MMSE score ranging from 19.11 to 18.88 (Cohen-d=0.216). Adjusted regression analyses revealed that depressive symptoms at baseline (B = 0.696; p = 0.048; R² = 0.19) and cognitive function at baseline (B = 0.444; p < 0.001; R² = 0.26) were predictive of their respective deteriorations over the follow-up period. Conclusion: Depressive symptoms and cognitive decline place a significant burden on public health systems in aging societies. These findings underscore the importance of continuous monitoring and early intervention strategies to mitigate their impact and enhance the quality of life for older adults.
Posted: 05 March 2025
of 15